Program
AD-1161
A development code.
Its studies are mostly in Prostatic Hyperplasia, led by Yuhan.
Furthest: phase 1, since Jul 29, 20253 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Yuhan | 32 open or running | phase 1since Jul 29, 2025 | Jul 29, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2025First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT07103278 · 44 enrolled · South Korea
- Jul 15, 20262 phase 1 studies in Prostatic HyperplasiaNCT07715305, NCT07722871
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722871Prostatic Hyperplasia · South Korea | 1 | Not yet recruiting | Oct 2026 | 44 |
| NCT07715305Prostatic Hyperplasia · South Korea | 1 | Not yet recruiting | Aug 2026 | 44 |
| NCT07103278Prostatic Hyperplasia · South Korea | 1 | Completed | Mar 7, 2026 | 44 |
How it is read
Names in the registry
- “AD-1161”, 3 entries
Codes read as this program: AD1161.
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.